Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Macitentan> ?p ?o. }
Showing items 1 to 54 of
54
with 100 items per page.
- Macitentan abstract "Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH). The other two ERAs marketed as of 2014 are bosentan and ambrisentan. Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype. The drug received approval from the U.S. Food and Drug Administration (FDA) on October 13, 2013.".
- Macitentan atcPrefix "C02".
- Macitentan atcSuffix "KX04".
- Macitentan casNumber "441798-33-0".
- Macitentan chEBI "76607".
- Macitentan iupacName "N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide".
- Macitentan pubchem "16004692".
- Macitentan thumbnail Macitentan_skeletal.svg?width=300.
- Macitentan wikiPageExternalLink www.actelion.nl.
- Macitentan wikiPageID "36797118".
- Macitentan wikiPageRevisionID "601951248".
- Macitentan atcPrefix "2.0".
- Macitentan atcSuffix "KX04".
- Macitentan br "2".
- Macitentan c "19".
- Macitentan casNumber "441798".
- Macitentan chebi "76607".
- Macitentan chemspiderid "13134960".
- Macitentan excretion "2".
- Macitentan h "20".
- Macitentan hasPhotoCollection Macitentan.
- Macitentan iupacName "N-[5--6-[2-[oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide".
- Macitentan legalStatus "FDA approved drug".
- Macitentan legalUs "Rx-only".
- Macitentan metabolism "Hydrolysis, oxidation".
- Macitentan molecularWeight "588.273".
- Macitentan n "6".
- Macitentan o "4".
- Macitentan pregnancyUs "X".
- Macitentan pubchem "16004692".
- Macitentan routesOfAdministration "Oral".
- Macitentan s "1".
- Macitentan smiles "Brc1cccc3cNSNCCC".
- Macitentan stdinchi "1".
- Macitentan stdinchikey "JGCMEBMXRHSZKX-UHFFFAOYSA-N".
- Macitentan synonyms "ACT-064992".
- Macitentan tradename "Opsumit".
- Macitentan subject Category:Endothelin_receptor_antagonists.
- Macitentan type Drug.
- Macitentan type FunctionalSubstance.
- Macitentan comment "Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH). The other two ERAs marketed as of 2014 are bosentan and ambrisentan. Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype. The drug received approval from the U.S.".
- Macitentan label "Macitentan".
- Macitentan label "Macitentan".
- Macitentan label "Macitentan".
- Macitentan label "Macitentan".
- Macitentan sameAs Macitentan.
- Macitentan sameAs Macitentan.
- Macitentan sameAs Macitentan.
- Macitentan sameAs m.0ll0nkk.
- Macitentan sameAs Q6724151.
- Macitentan sameAs Q6724151.
- Macitentan wasDerivedFrom Macitentan?oldid=601951248.
- Macitentan depiction Macitentan_skeletal.svg.
- Macitentan isPrimaryTopicOf Macitentan.
